218 related articles for article (PubMed ID: 36622841)
21. PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature.
Cytawa W; Hartrampf P; Lass P; Kircher M; Polat B; Buck AK; Lapa C
Clin Genitourin Cancer; 2021 Aug; 19(4):e235-e247. PubMed ID: 33906800
[TBL] [Abstract][Full Text] [Related]
22. [Trends of Radiotheranostics Research].
Hosono M
Gan To Kagaku Ryoho; 2022 Aug; 49(8):809-812. PubMed ID: 36046961
[TBL] [Abstract][Full Text] [Related]
23. An introduction to the clinical practice of theranostics in oncology.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine tumor theranostics.
Ichikawa Y; Kobayashi N; Takano S; Kato I; Endo K; Inoue T
Cancer Sci; 2022 Jun; 113(6):1930-1938. PubMed ID: 35271754
[TBL] [Abstract][Full Text] [Related]
25. Next-level precision medicine: why the theragnostic approach is the future.
Iacomino A; Rapa M; Gatta G; DI Grezia G; Cuccurullo V
Q J Nucl Med Mol Imaging; 2024 Jun; 68(2):152-159. PubMed ID: 38860276
[TBL] [Abstract][Full Text] [Related]
26. Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177.
Manogue CE; Chen W; Mazza A; Dang A; Lewis B; Wallis CJD; Layton J; Barata P; Sartor O; Harris KM
Pract Radiat Oncol; 2022; 12(4):300-304. PubMed ID: 35717044
[TBL] [Abstract][Full Text] [Related]
27. The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey.
Borkowetz A; Linxweiler J; Fussek S; Wullich B; Saar M;
Urol Int; 2022; 106(11):1126-1135. PubMed ID: 36195073
[TBL] [Abstract][Full Text] [Related]
28. [Oncological theranostics in nuclear medicine].
Laschinsky C; Herrmann K; Fendler W; Nader M; Lahner H; Hadaschik B; Sandach P
Radiologie (Heidelb); 2022 Oct; 62(10):875-884. PubMed ID: 36112174
[TBL] [Abstract][Full Text] [Related]
29. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
Jadvar H
AJR Am J Roentgenol; 2017 Aug; 209(2):277-288. PubMed ID: 28463538
[TBL] [Abstract][Full Text] [Related]
30. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
32. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
33. [Radiotheranostics in endocrinology and oncoendocrinology].
Rumyanstsev RO
Probl Endokrinol (Mosk); 2021 Feb; 67(1):8-12. PubMed ID: 33586387
[TBL] [Abstract][Full Text] [Related]
34. Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.
Yazdani E; Geramifar P; Karamzade-Ziarati N; Sadeghi M; Amini P; Rahmim A
Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38248059
[TBL] [Abstract][Full Text] [Related]
35. (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer.
Velikyan I
Pharmaceuticals (Basel); 2020 Mar; 13(3):. PubMed ID: 32151049
[TBL] [Abstract][Full Text] [Related]
36. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
37. Peptide and pseudo-peptide.
Mirzaei S; Lipp RW
Q J Nucl Med Mol Imaging; 2020 Dec; 64(4):364-370. PubMed ID: 33045822
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.
Hawkey NM; Sartor AO; Morris MJ; Armstrong AJ
Clin Adv Hematol Oncol; 2022 Apr; 20(4):227-238. PubMed ID: 35389387
[TBL] [Abstract][Full Text] [Related]
39. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Emmett L
Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
[TBL] [Abstract][Full Text] [Related]
40. Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
Feuerecker B; Kratochwil C; Ahmadzadehfar H; Morgenstern A; Eiber M; Herrmann K; Pomykala KL
J Nucl Med; 2023 May; 64(5):685-692. PubMed ID: 37055224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
